Gaps in the evidence for treatment decisions in cystic fibrosis

A systematic review

Nicola Jane Rowbotham, Sherie Smith, Andrew P. Prayle, Karen A Robinson, Alan Robert Smyth

Research output: Contribution to journalArticle

Abstract

Introduction: Cystic fibrosis (CF) is a multisystem disorder. Treatment is complex and evidence for treatment decisions may be absent. Characterising gaps in the research evidence will highlight treatment uncertainties and help prioritise research questions. We systematically identified the evidence gaps for treatment decisions in CF. Methods: We searched for systematic reviews and guidelines on treatment interventions in CF. Two researchers identified eligible reviews with arbitration from a third. Using a structured framework, we extracted and characterised evidence gaps. Results: There were 73 reviews and 21 guidelines that met our inclusion criteria. From these, we identified 148 evidence gaps across a range of treatment areas. We found 111 evidence gaps through systematic reviews and a further 37 from guidelines. The reason for an evidence gap could only be reliably characterised for systematic reviews. In most cases, there was more than one explanation - most commonly few or no trials (97/111 evidence gaps). Other important factors leading to evidence gaps were small sample size (49/111), inadequate duration of follow-up (38/111) or intervention (37/111) and factors relating to outcomes (35/111). Evidence gaps from both systematic reviews and guidelines fell into the following categories: Respiratory (91); Gastrointestinal (20); PhysiotherapyandExercise (16); Musculoskeletal (6); Endocrine (4); Basic defect of CF (8); Psychosocial (2); Ears, Nose and Throat (1). Conclusions: We have compiled an up-to-date list of treatment uncertainties in CF and the reasons for these uncertainties. These can be used as a resource to aid researchers and funders when planning future trials. PROSPERO registration number: Pre-results; CRD42015030111.

Original languageEnglish (US)
JournalThorax
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Cystic Fibrosis
Guidelines
Uncertainty
Research Personnel
Negotiating
Pharynx
Nose
Research
Sample Size
Ear

Keywords

  • cystic fibrosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Gaps in the evidence for treatment decisions in cystic fibrosis : A systematic review. / Rowbotham, Nicola Jane; Smith, Sherie; Prayle, Andrew P.; Robinson, Karen A; Smyth, Alan Robert.

In: Thorax, 01.01.2018.

Research output: Contribution to journalArticle

Rowbotham, Nicola Jane ; Smith, Sherie ; Prayle, Andrew P. ; Robinson, Karen A ; Smyth, Alan Robert. / Gaps in the evidence for treatment decisions in cystic fibrosis : A systematic review. In: Thorax. 2018.
@article{1f6001eebd314853ba509061cb60d80e,
title = "Gaps in the evidence for treatment decisions in cystic fibrosis: A systematic review",
abstract = "Introduction: Cystic fibrosis (CF) is a multisystem disorder. Treatment is complex and evidence for treatment decisions may be absent. Characterising gaps in the research evidence will highlight treatment uncertainties and help prioritise research questions. We systematically identified the evidence gaps for treatment decisions in CF. Methods: We searched for systematic reviews and guidelines on treatment interventions in CF. Two researchers identified eligible reviews with arbitration from a third. Using a structured framework, we extracted and characterised evidence gaps. Results: There were 73 reviews and 21 guidelines that met our inclusion criteria. From these, we identified 148 evidence gaps across a range of treatment areas. We found 111 evidence gaps through systematic reviews and a further 37 from guidelines. The reason for an evidence gap could only be reliably characterised for systematic reviews. In most cases, there was more than one explanation - most commonly few or no trials (97/111 evidence gaps). Other important factors leading to evidence gaps were small sample size (49/111), inadequate duration of follow-up (38/111) or intervention (37/111) and factors relating to outcomes (35/111). Evidence gaps from both systematic reviews and guidelines fell into the following categories: Respiratory (91); Gastrointestinal (20); PhysiotherapyandExercise (16); Musculoskeletal (6); Endocrine (4); Basic defect of CF (8); Psychosocial (2); Ears, Nose and Throat (1). Conclusions: We have compiled an up-to-date list of treatment uncertainties in CF and the reasons for these uncertainties. These can be used as a resource to aid researchers and funders when planning future trials. PROSPERO registration number: Pre-results; CRD42015030111.",
keywords = "cystic fibrosis",
author = "Rowbotham, {Nicola Jane} and Sherie Smith and Prayle, {Andrew P.} and Robinson, {Karen A} and Smyth, {Alan Robert}",
year = "2018",
month = "1",
day = "1",
doi = "10.1136/thoraxjnl-2017-210858",
language = "English (US)",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Gaps in the evidence for treatment decisions in cystic fibrosis

T2 - A systematic review

AU - Rowbotham, Nicola Jane

AU - Smith, Sherie

AU - Prayle, Andrew P.

AU - Robinson, Karen A

AU - Smyth, Alan Robert

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Cystic fibrosis (CF) is a multisystem disorder. Treatment is complex and evidence for treatment decisions may be absent. Characterising gaps in the research evidence will highlight treatment uncertainties and help prioritise research questions. We systematically identified the evidence gaps for treatment decisions in CF. Methods: We searched for systematic reviews and guidelines on treatment interventions in CF. Two researchers identified eligible reviews with arbitration from a third. Using a structured framework, we extracted and characterised evidence gaps. Results: There were 73 reviews and 21 guidelines that met our inclusion criteria. From these, we identified 148 evidence gaps across a range of treatment areas. We found 111 evidence gaps through systematic reviews and a further 37 from guidelines. The reason for an evidence gap could only be reliably characterised for systematic reviews. In most cases, there was more than one explanation - most commonly few or no trials (97/111 evidence gaps). Other important factors leading to evidence gaps were small sample size (49/111), inadequate duration of follow-up (38/111) or intervention (37/111) and factors relating to outcomes (35/111). Evidence gaps from both systematic reviews and guidelines fell into the following categories: Respiratory (91); Gastrointestinal (20); PhysiotherapyandExercise (16); Musculoskeletal (6); Endocrine (4); Basic defect of CF (8); Psychosocial (2); Ears, Nose and Throat (1). Conclusions: We have compiled an up-to-date list of treatment uncertainties in CF and the reasons for these uncertainties. These can be used as a resource to aid researchers and funders when planning future trials. PROSPERO registration number: Pre-results; CRD42015030111.

AB - Introduction: Cystic fibrosis (CF) is a multisystem disorder. Treatment is complex and evidence for treatment decisions may be absent. Characterising gaps in the research evidence will highlight treatment uncertainties and help prioritise research questions. We systematically identified the evidence gaps for treatment decisions in CF. Methods: We searched for systematic reviews and guidelines on treatment interventions in CF. Two researchers identified eligible reviews with arbitration from a third. Using a structured framework, we extracted and characterised evidence gaps. Results: There were 73 reviews and 21 guidelines that met our inclusion criteria. From these, we identified 148 evidence gaps across a range of treatment areas. We found 111 evidence gaps through systematic reviews and a further 37 from guidelines. The reason for an evidence gap could only be reliably characterised for systematic reviews. In most cases, there was more than one explanation - most commonly few or no trials (97/111 evidence gaps). Other important factors leading to evidence gaps were small sample size (49/111), inadequate duration of follow-up (38/111) or intervention (37/111) and factors relating to outcomes (35/111). Evidence gaps from both systematic reviews and guidelines fell into the following categories: Respiratory (91); Gastrointestinal (20); PhysiotherapyandExercise (16); Musculoskeletal (6); Endocrine (4); Basic defect of CF (8); Psychosocial (2); Ears, Nose and Throat (1). Conclusions: We have compiled an up-to-date list of treatment uncertainties in CF and the reasons for these uncertainties. These can be used as a resource to aid researchers and funders when planning future trials. PROSPERO registration number: Pre-results; CRD42015030111.

KW - cystic fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85054684913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054684913&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2017-210858

DO - 10.1136/thoraxjnl-2017-210858

M3 - Article

JO - Thorax

JF - Thorax

SN - 0040-6376

ER -